Myeloid cells infiltrating tumors are gaining ever growing attention in the last years because
their pro-tumor and immunosuppressive functions are relevant for disease progression and …

Molecularly targeted therapies are rapidly growing with respect to their clinical development
and impact on cancer treatment due to their highly selective anti-tumor action. However …

Purpose Glycoprotein NMB (gpNMB), a novel transmembrane protein overexpressed in
40% to 60% of breast cancers, promotes metastases in animal models and is a prognostic …

Glycoprotein non-metastatic melanoma protein B (GPNMB) is a transmembrane protein
enriched on the cell surface of cancer cells, including melanoma, glioblastoma, and triple …

Although MSCs have been widely recognized to have therapeutic potential in the repair of
injured or diseased tissues, it remains unclear how functional activities of mesenchymal …

Non-metastatic glycoprotein melanoma protein B (GPNMB), also known as osteoactivin (OA)
is expressed in a wide array of tumors and represents an emerging target for drug …

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease
worldwide. Gpnmb is classified as a type 1 membrane protein and its soluble form is …

Survival outcomes for osteosarcoma have plateaued since the 1980s, and patients with
relapsed or refractory disease have a particularly dismal outcome. Treatment options for …

Novel urinary kidney safety biomarkers have been identified recently that may outperform or
add value to the conventional renal function biomarkers, blood urea nitrogen (BUN) and …

Glycoprotein non-metastatic melanoma protein B (GPNMB) is a glycoprotein that is highly
expressed in various types of cancer, including osteosarcoma. However, its cellular …